How many stocks does RTW INVESTMENTS, LP own?

As of Q1 2026, RTW INVESTMENTS, LP holds 88 positions in their 13F portfolio.

What is RTW INVESTMENTS, LP's largest holding?

MDGL at 10.4% of portfolio, worth $1B.

What is RTW INVESTMENTS, LP's total portfolio value?

$10B as of Q1 2026, tracked across 88 holdings.

Is RTW INVESTMENTS, LP a hedge fund?

RTW INVESTMENTS, LP is an institutional investment manager required to file SEC 13F reports. This includes hedge funds, mutual funds, pension funds, and other institutions managing over $100M.

How often does RTW INVESTMENTS, LP report?

13F filings are due quarterly, approximately 45 days after each quarter end.

How has RTW INVESTMENTS, LP's portfolio changed in Q1 2026?

View RTW INVESTMENTS, LP's latest portfolio changes, new positions, and exits for Q1 2026 on HoldingsIntel.

What is RTW INVESTMENTS, LP's investment strategy?

RTW INVESTMENTS, LP is classified as a Balanced Allocator fund based on HoldingsIntel's Fund DNA analysis of 6 behavioral dimensions.

RTW INVESTMENTS, LP Holdings Q1 2026 - Portfolio & Conviction Scores | HoldingsIntel

RTW INVESTMENTS, LP

Institutional investor · Portfolio as of Q1 2026

Elite(4.5 / 5.0)

$10B

AUM

Positions

New

Q1 2026

Filing Period

Quarterly Portfolio Change

SEC EDGAR SourceSEC Filings

RTW INVESTMENTS, LP manages $10B across 88 positions as of Q1 2026. Top holdings: MDGL (10.4%), INSM (7.9%), PTGX (5.3%). Fund DNA: Balanced Allocator. HoldingsIntel Rating: 4.5/5.0.

Q1 2026 Summary

Active quarter - 9 new positions, 12 exits, 30 increased. Top move: CGON (INCREASED, conviction 93). Portfolio: $10.0B across 88 positions.

Portfolio Allocation

Top holdings by portfolio weight

MDGL10.38%

INSM7.88%

PTGX5.31%

PTCT5.25%

ARGX5.16%

CGON4.70%

CELC3.45%

TNGX2.77%

ERAS2.60%

NTRA2.49%

Other2.38%

Similar Funds

Funds with similar investing DNA

ARK Investment Management LLC

Position Outcomes

Best and worst performing positions by estimated return

Top Winners

NTRA27Q held

NATERA INC

Avg $42.13 · $181.6M est. P&L

Est. P&L

+344.76%

PTGX27Q held

PROTAGONIST THERAPEUTICS INC

Avg $24.36 · $393.7M est. P&L

Est. P&L

+319.54%

SYRE10Q held

SPYRE THERAPEUTICS INC

Avg $23.46 · $214.7M est. P&L

Est. P&L

+219.30%

Top Losers

Upgrade to Pro to see the worst-performing positions.

View plans

Cost basis estimates based on full filing history using quarter-end prices. Actual transaction prices are not disclosed in 13F filings.

Top Holdings88 positions

Export CSV(Pro)

Activity:

Stock	Shares	Value	Weight	Price Trend	Avg Buy	Est. P&L	Held	Conviction
MDGL MADRIGAL PHARMACEUTICALS INC	2M	$1B	10.4%	—	$265.36	+97.35%	12 qtrssince 2023-Q2	Unchanged 0
INSM INSMED INC	4.8M	$791.9M	7.9%	—	$92.19	+18.38%	12 qtrssince 2023-Q2	Increased 61
PTGX PROTAGONIST THERAPEUTICS INC	5.1M	$533.2M	5.3%	—	$24.36	+319.54%	27 qtrssince 2019-Q3	Unchanged 0
PTCT PTC THERAPEUTICS INC	7.7M	$527.8M	5.3%	—	$43.73	+63.43%	29 qtrssince 2019-Q1	Unchanged 0
ARGX ADR ARGENX SE	709,446	$518.1M	5.2%	—	$375.03	+116.54%	29 qtrssince 2019-Q1	Increased 64
CGON CG ONCOLOGY INC	7M	$472.7M	4.7%	—	$53.16	+25.91%	9 qtrssince 2024-Q1	Increased 93
CELC CELCUITY INC	3M	$346.9M	3.5%	—	$106.05	+29.83%	2 qtrssince 2025-Q4	Increased 92
TNGX TANGO THERAPEUTICS INC	13.3M	$278.2M	2.8%	—	$11.18	+83.93%	2 qtrssince 2025-Q4	Increased 85
ERAS ERASCA INC	16.2M	$261.4M	2.6%	—	$14.00	-26.95%	2 qtrssince 2025-Q4	Increased 85
NTRA NATERA INC	1.3M	$250M	2.5%	—	$42.13	+344.76%	27 qtrssince 2019-Q3	Decreased 0
Showing 10 of 88 results.78 more with Pro.PROUpgrade to see all →